Eli Lilly likes what it sees in Adimab’s antibody R&D platform, opting to roll it out at sites in San Diego and New York to help its antibody discovery and optimization activities.

The big pharma group has been putting Adimab’s technology through its paces since 2010, but the new technology transfer deal represents a step up in their collaboration, and adds another big pharma partner to Adimab’s growing stable.

New Hampshire-based Adimab’s chief executive Tillman Gerngross said the deal with Lilly is a prime example of its strategy—starting out with small collaborations to showcase its technology and then broadening the relationship, either doing partner-funded discovery or transferring the platform for internal use.

Read More